RightFit
RecruitingNot applicable

A Study of Language Interpretation Solutions for People With Breast Cancer

RSMI HEALS (Health Equity Advances Through Language Solutions) (AI)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study compares three ways to use remote interpreters during cancer visits: interpreting as people speak, interpreting after they pause, and interpreting after they pause by video. It is for adults who prefer Spanish or Mandarin and have trouble speaking English. The study description focuses on stage II or III breast cancer, but the entry rules also allow gastrointestinal cancer (cancer in the digestive system).

The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting/RSMI (Arm 1), versus Remote Consecutive Medical Interpreting/RCMI (Arm 2) and versus Remote Consecutive Video Medical Interpreting/RCVI (Arm 3) in breast cancer outpatient clinical encounters with Spanish- and Mandarin-speaking patients with Limited English Proficiency/LEP (Stages II and III disease) and English- speaking providers (who do not speak Spanish/Mandarin). In Phase 2, there will be a sequential mixed-methods explanatory, multi-stakeholder process evaluation to gather implementation potential data.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Phase 1 patients: Age 18 or older.
  • Patients: Prefer Spanish or Mandarin for health care and cannot speak English very well.
  • Patients: Have breast cancer or cancer in the digestive system.
  • Patients: Will have their first or second visit with an MSK cancer care team.
  • All participants: Agree to have their voices recorded.
  • Phase 1 providers: Care for patients with breast cancer or cancer in the digestive system, such as cancer doctors or nurses.
  • Providers: Do not speak Spanish, Mandarin, or both. Providers who speak one but not the other may join.
  • Phase 2 staff: Work or worked at a study clinic during Phase 1. Phase 2 patients come from Phase 1.

Who can't join

  • Patients: Have severe current mental health symptoms that prevent them from completing study tasks or giving informed consent (understanding and agreeing to join).
  • Patients: Have thinking or memory problems, such as delirium (confusion) or dementia, that prevent informed consent or collection of study information.
  • No exclusion rules are listed for providers or Phase 2 clinic staff.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: Phase I Patients * Age \>=18 years (per EMR) * Preferred language for healthcare is Spanish or Mandarin (per self-report) * Limited English Proficient; cannot speak English "very well" (per self-report) * Diagnosis of breast cancer or gastrointestinal (per EMR) * Will be visiting MSK oncology teams for the first or second appointment (per EMR) * Agrees to be audio-recorded (per self-report) Phase 1 Providers * Breast or gastrointestinal cancer provider who sees patients (e.g., breast or gastrointestinal oncologists, advanced practice providers, and/or nurses) * Does not speak Spanish and/or Mandarin; providers who speak one language and not the other may participate (e.g., speaks Spanish but not Mandarin) (per self-report) * Agrees to be audio-record (per self-report) Phase 2 (clinic staff only; patient participants will be drawn from Phase 1) * Is a staff member who works/worked in one of the study clinic sites during the period of Phase 1 RCT study activities * Agrees to be audio-recorded (per self-report) Exclusion Criteria: Phase 1 Patients * Has significant psychiatric disturbance (i.e., acute psychiatric symptoms) sufficient to preclude completion of the assessments, interviews, or informed consent (per EMR, patient's care team, or study team) * Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patients, care team, or study team) Phase I Providers * None Phase 2 (clinic staff only; Phase 1 patient participants follow above criteria) * None

Study sites (8)

NJ

NY